Bristol-Myers Squibb Co (BMY) Position Reduced by Gilman Hill Asset Management LLC

Gilman Hill Asset Management LLC reduced its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 13.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,712 shares of the biopharmaceutical company’s stock after selling 1,890 shares during the quarter. Gilman Hill Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $747,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in BMY. Blue Chip Partners Inc. boosted its stake in Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. lifted its stake in shares of Bristol-Myers Squibb by 0.4% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 15 shares during the last quarter. Shayne & CO. LLC lifted its stake in shares of Bristol-Myers Squibb by 0.6% in the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 24 shares during the last quarter. Chilton Investment Co. LLC lifted its stake in shares of Bristol-Myers Squibb by 0.5% in the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 26 shares during the last quarter. Finally, Greenleaf Trust lifted its stake in shares of Bristol-Myers Squibb by 0.4% in the 2nd quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock valued at $535,000 after purchasing an additional 39 shares during the last quarter. 69.67% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director Theodore R. Samuels II acquired 4,000 shares of the business’s stock in a transaction on Friday, December 15th. The stock was bought at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the purchase, the director now owns 22,000 shares in the company, valued at $1,370,600. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is owned by insiders.

Shares of Bristol-Myers Squibb Co (NYSE BMY) traded up $0.34 during mid-day trading on Friday, hitting $62.81. The stock had a trading volume of 5,489,236 shares, compared to its average volume of 5,400,000. The firm has a market cap of $102,800.00, a PE ratio of 24.73, a PEG ratio of 2.22 and a beta of 1.18. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Co has a fifty-two week low of $46.01 and a fifty-two week high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same period last year, the firm earned $0.77 EPS. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. research analysts expect that Bristol-Myers Squibb Co will post 2.99 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.55%. The ex-dividend date is Thursday, January 4th. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is currently 62.99%.

A number of brokerages recently issued reports on BMY. UBS Group reissued a “buy” rating and set a $72.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Vetr raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price target for the company in a research note on Monday, October 9th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 12th. Finally, Citigroup raised their price objective on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a report on Wednesday, October 18th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $65.05.

WARNING: This article was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://ledgergazette.com/2018/01/13/gilman-hill-asset-management-llc-reduces-position-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply